Considering the important roles of immune dysfunction during lung cancer occurrence and progression (Datar and Schalper, 2016; Mascaux et al., 2019), the potential effects of HSD17B4 in immunoregulation might provide new clues for NSCLC immunotherapy. Here, HSD17B4 is linked to lung carcinoma.